Nivolumab (Opdivo / Opdyta) Side Effects: What to Watch For
Most people on nivolumab have mild, manageable side effects — tiredness, itching, a rash, loose motions, aching joints. A smaller number develop immune-related reactions, where the released immune system inflames a healthy organ. Those are the ones that matter. Opdivo, Opdyta and Tishtha are three names for the same molecule and share the same side-effect profile. This page sets out what is common, what is serious, how it is monitored, and when each reaction typically appears.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
What are the most common side effects of nivolumab?
The side effects reported most often with nivolumab are tiredness, itching, a skin rash, loose motions, nausea or reduced appetite, joint and muscle aches, cough, constipation and fever. Tiredness is the one people report most, and the hardest to put a number on. Most of these are mild to moderate and are managed with supportive care while treatment continues.
- Tiredness — the most frequent effect of all. It is worth flagging when it is new or suddenly worse, because persistent tiredness is also how an underactive thyroid and an underactive adrenal gland first announce themselves. See fatigue during immunotherapy.
- Itching and skin rash — usually the earliest reaction to appear. A mild itchy rash is common. A rash with blisters, peeling skin, or sores in the mouth or eyes is not, and is treated as urgent.
- Loose motions — a small increase over your usual bowel habit is common. Counting is what separates this from colitis; see counting loose motions accurately.
- Nausea, reduced appetite, constipation — usually mild, and usually settled with the supportive medication your team prescribes.
- Joint and muscle aches — common, and occasionally the beginning of an inflammatory arthritis or myositis that needs treatment in its own right.
- Cough and infusion-day reactions — a mild cough is often unremarkable, but a new or changing cough is also the first sign of lung inflammation. Chills, flushing or fever during the drip itself are infusion reactions and are managed in the day-care unit.
A mild symptom is not automatically a minor one. Almost every serious reaction on this page starts as something small. That is why the advice is always to report a new symptom to the oncology team rather than judge its severity at home.
Which nivolumab side effects are serious?
The serious side effects of nivolumab are the immune-related adverse events — inflammation of the bowel, lungs, liver, heart, pituitary, adrenal glands, kidneys, pancreas or skin. Severe reactions occur in a minority of patients on single-agent nivolumab, according to immune-toxicity management guidance from ASCO, ESMO and NCCN. They can progress quickly. They are treated with corticosteroids, not at home.
- Colitis — inflammation of the bowel. Frequent loose motions, cramping, or blood or mucus in the stool. Do not self-treat with anti-diarrhoeal medicine; contact the oncology team the same day.
- Pneumonitis — inflammation of the lungs. A new or worsening cough, or breathlessness doing something that was easy last week. This needs same-day assessment, not watchful waiting.
- Hepatitis — inflammation of the liver. Usually silent, and usually picked up on the routine blood tests taken before a cycle. That is why those tests are not optional.
- Myocarditis — inflammation of the heart muscle. Rare, and the most dangerous reaction on this list. Chest pain, palpitations or breathlessness at rest means going to the nearest emergency department immediately.
- Hypophysitis and adrenal insufficiency — the pituitary or adrenal glands stop producing hormones. Severe headache, profound weakness, dizziness on standing, vomiting. An adrenal crisis is a medical emergency and is treated in hospital.
- Thyroid inflammation — the most common endocrine reaction. It often begins with a short overactive phase before settling into an underactive thyroid that needs lifelong tablets.
- Nephritis — inflammation of the kidneys, usually detected as a rising creatinine on blood tests rather than as a symptom.
- Immunotherapy-induced diabetes — uncommon, sudden, and permanent. Excessive thirst, passing large volumes of urine and rapid weight loss need urgent testing.
- Severe skin reactions — blistering, peeling skin, or ulcers in the mouth or eyes. Treated as an emergency.
How are nivolumab side effects monitored?
Nivolumab side effects are monitored two ways: routine blood tests before every cycle, and what the patient reports between cycles. Liver enzymes, kidney function, thyroid hormones, blood counts and often blood sugar are checked each time. Two of the most serious reactions, hepatitis and nephritis, are usually silent and are found only this way.
Baseline tests are done before the first dose, along with a careful history of autoimmune conditions, transplants and current medicines. In India, hepatitis B and C status and tuberculosis risk are normally checked first as well. From then on the pattern repeats before each infusion, and the results are reviewed before the pharmacy releases the drug. A borderline result is a reason to hold a dose, not a formality.
When a reaction is confirmed, treatment follows a well-established pattern set out by ASCO, ESMO and NCCN. Mild reactions may be managed with supportive care while immunotherapy continues. Moderate ones usually mean holding the next dose and starting corticosteroids. Severe ones mean stopping the dose, admitting the patient, and using higher-dose steroids, with a second immunosuppressant added if the reaction does not settle. Steroids are then tapered slowly over weeks rather than stopped abruptly. Related reading: steroids for immunotherapy side effects, why steroids are tapered slowly and rechallenge after an immune reaction.
Checkpoint inhibitor infusions are day-care treatment at CION, and response-assessment PET-CT is coordinated at partner imaging centres rather than performed in-house.
Who this is not for
Most people with cancer in India are not candidates for nivolumab. Eligibility depends on the specific cancer type and stage, on the CDSCO-approved indication for that diagnosis, on which line of treatment has already been tried, and often on a biomarker result such as PD-L1 expression or MSI-High / mismatch-repair status. As of August 2026 the Indian approvals cover selected advanced cancers — melanoma, non-small cell lung cancer, kidney (renal cell) cancer, head and neck cancer and urothelial bladder cancer among them — not cancer in general. A person whose diagnosis is not on that list will not be offered it, and that is a clinical fact rather than a rationing decision.
Beyond eligibility, nivolumab is generally avoided or used only with great caution in people with an active autoimmune disease, in organ transplant recipients, and in anyone already on high-dose immunosuppression, because releasing the immune brake can worsen the underlying condition or trigger rejection of a transplanted organ. Poor performance status, uncontrolled infection and pregnancy are further reasons an oncologist may decide against it. Existing thyroid disease or interstitial lung disease does not automatically rule it out, but it changes the monitoring plan and it raises the stakes of a reaction.
It also does not work for everyone who is eligible. A substantial proportion of patients who meet every criterion see no benefit, which is one reason response-assessment imaging is scheduled early. Whether nivolumab is appropriate for a particular person, alone or in combination, can only be decided by their treating oncology team from their own reports.
When do nivolumab side effects usually appear?
Different organs are affected at different points in treatment, and that pattern is one of the most useful things to know. Skin reactions come first, usually within two to six weeks. Thyroid, bowel and liver reactions follow over the next two to three months. Pituitary, adrenal and kidney problems tend to arrive later. Myocarditis is the exception — rare, but usually early.
| Immune reaction | Typically starts | First signs to report |
|---|---|---|
| Infusion reaction | During or within hours of a drip | Chills, flushing, fever, itching, breathlessness on the day |
| Skin rash, itching | 2–6 weeks | Itchy patches, dry skin, a spreading rash |
| Myocarditis (rare) | Usually within the first 6 weeks | Chest pain, palpitations, breathlessness at rest — emergency |
| Thyroid changes | 4–12 weeks | Unusual tiredness, feeling cold, weight change, palpitations |
| Colitis | 5–10 weeks | More loose motions than your normal, cramping, blood or mucus |
| Hepatitis | 6–14 weeks | Silent on blood tests first; later yellow eyes, dark urine |
| Pneumonitis | 8–14 weeks | New or worsening cough, breathlessness on light activity |
| Hypophysitis, adrenal failure | 8–16 weeks | Persistent headache, severe weakness, dizziness on standing, vomiting |
| Nephritis | 12–24 weeks | Usually silent; rising creatinine on routine blood tests |
| Immune diabetes (rare) | Any time, more often after 12 weeks | Excessive thirst, passing large volumes of urine, rapid weight loss |
These windows describe typical patterns reported in ASCO and ESMO immune-toxicity management guidance, as of August 2026. They are a guide to what to expect, not a rule — an immune-related reaction can begin at any point in treatment, and some begin after it ends. For the picture across all checkpoint inhibitors, see when immunotherapy side effects start.
Does nivolumab with ipilimumab cause more side effects?
Yes. Adding ipilimumab to nivolumab releases two immune brakes instead of one, and the side-effect profile changes with it. Immune reactions are more frequent on the combination, more often severe, and usually earlier. This matters on a side-effects page because the same molecule behaves very differently depending on what it is paired with.
| What changes | Nivolumab alone | Nivolumab + ipilimumab |
|---|---|---|
| Immune brakes released | One (PD-1) | Two (PD-1 and CTLA-4) |
| Immune reactions overall | Common, mostly mild to moderate | More common, and more often moderate to severe |
| Severe reactions | A minority of patients | Substantially more frequent than with nivolumab alone |
| When they typically start | Often between weeks 4 and 14 | Often earlier, within the first one or two cycles |
| Corticosteroids needed | Less often | More often, and usually for longer |
| Treatment stopped for toxicity | Less often | More often |
| Monitoring | Blood tests before every cycle | The same tests, read more closely, with a lower threshold to hold a dose |
This is a known trade-off rather than an error. The combination is used in specific situations where the treating oncologist judges the potential benefit worth the higher risk, and it is paired with closer monitoring. Where that judgement is made is set out on nivolumab plus ipilimumab versus single-agent nivolumab. The same toxicity pattern is described in ASCO and ESMO immune-toxicity guidance for every anti-PD-1 and anti-CTLA-4 pairing, not for this one alone.
Can nivolumab side effects start after treatment has stopped?
Yes. Nivolumab changes how the immune system behaves, and that change outlasts the final infusion. Immune-related reactions have been reported weeks and, less often, months after a last dose. Thyroid and pituitary damage can be permanent, leaving a person on hormone replacement long term.
The practical consequence is simple. Anyone who has received a checkpoint inhibitor should tell every doctor who treats them afterwards, including in an emergency department, that they had immunotherapy and roughly when. A doctor who does not know that will not think of an immune reaction, and steroid treatment for colitis looks nothing like antibiotic treatment for an infection. See delayed immune reactions after stopping, monitoring after stopping immunotherapy and always tell doctors about immunotherapy.
Side effects are also not a progress report. Some studies have observed an association between certain immune reactions and response, but the link is not reliable for any individual patient. Whether treatment is doing what it is intended to do is judged on response-assessment imaging and clinical review, not on how unwell you feel in week six. See do side effects mean immunotherapy is working.
Long-term data on immune-related effects years after treatment is still maturing, and the honest position on several of these questions is that we do not yet know.
Nivolumab Side Effects: Frequently Asked Questions
What are the most common side effects of nivolumab?
The side effects reported most often with nivolumab are tiredness, itching, a skin rash, loose motions, nausea or reduced appetite, joint and muscle aches, cough, constipation and fever. Tiredness is the single most commonly reported effect. Most of these are mild to moderate and are managed with supportive care while treatment continues. The important point is that a mild symptom is not automatically a minor one. Almost every serious immune reaction described on this page begins as something small — a slightly looser bowel habit, a faint rash, new tiredness — which is why any new symptom is reported to the oncology team rather than judged at home.
Which nivolumab side effects are serious?
The serious ones are the immune-related adverse events, in which the released immune system inflames a healthy organ. The reactions that need urgent attention are colitis, pneumonitis, hepatitis, myocarditis, pituitary or adrenal failure, severe skin reactions, nephritis and immunotherapy-induced diabetes. Severe reactions occur in a minority of patients on single-agent nivolumab, according to immune-toxicity management guidance from ASCO, ESMO and NCCN, but they can progress quickly and a few of them are life-threatening. They are treated with corticosteroids and, when a reaction does not settle, with further immunosuppression. They are not managed at home.
When do nivolumab side effects usually appear?
Different organs tend to be affected at different points in treatment. Skin reactions are usually the earliest, at around two to six weeks. Thyroid changes follow at roughly four to twelve weeks, colitis at five to ten weeks, liver inflammation at six to fourteen weeks and pneumonitis at eight to fourteen weeks. Pituitary and adrenal problems tend to arrive later, and kidney inflammation later again. Myocarditis is the exception: it is rare, but usually early, often within the first six weeks. These windows describe typical patterns in guideline literature rather than rules, and reactions tend to arrive sooner when nivolumab is combined with ipilimumab.
Does nivolumab with ipilimumab cause more side effects than nivolumab alone?
Yes, and predictably so. Combining nivolumab, an anti-PD-1 antibody, with ipilimumab, an anti-CTLA-4 antibody, releases two separate immune brakes rather than one. Immune-related reactions are more frequent on the combination, tend to be more severe, and usually begin earlier — often within the first one or two cycles rather than after two or three months. More patients need corticosteroids, and more stop treatment because of toxicity. That is a known trade-off rather than a mistake: the combination is chosen in specific situations where the treating oncologist judges the potential benefit worth the higher risk, and it is paired with closer monitoring.
Do Opdivo, Opdyta and Tishtha have the same side effects?
Yes. All three names describe the same active molecule, nivolumab. Opdivo is the originator brand used outside India, Opdyta is the same originator product registered under its Indian brand name, and Tishtha is the Zydus Lifesciences biosimilar launched in India in January 2026. A biosimilar is approved on the basis that it behaves like the reference product in the body, and CDSCO requires comparative quality and safety data before clearing one. The side-effect profile and the monitoring schedule are therefore the same. The differences between these names are about manufacturer and price, not about what the medicine does to healthy organs.
Can nivolumab side effects start after treatment has stopped?
Yes. Nivolumab changes how the immune system behaves, and that change outlasts the final infusion. Immune-related reactions have been reported weeks, and less often months, after a last dose. Thyroid and pituitary damage can be permanent, leaving a person on hormone replacement long term. The practical consequence is simple: anyone who has received a checkpoint inhibitor should tell every doctor who treats them afterwards, including in an emergency department, that they had immunotherapy and roughly when. A doctor who does not know that will not think of an immune reaction, and the treatment for one is quite different from the treatment for an ordinary infection.